Nobuharu Hanaoka

Osaka University of Pharmaceutical Sciences

Papers

1

Total Citations

2

H-Index

1

About

Nobuharu Hanaoka is a leading figure in thoracic oncology, with a primary focus on lung cancers, malignant pleural mesotheliomas, and thymic epithelial tumors. His most significant contribution lies in the development of evidence-based medical practice guidelines, particularly as a key editor for the Japan Lung Cancer Society’s comprehensive 2024 guidelines. Hanaoka’s work on the chapter dedicated to thymic epithelial tumors has provided critical, standardized recommendations that shape clinical decision-making for these rare and complex malignancies. While his most-cited paper currently holds 2 citations, his impact is more profoundly measured by the widespread adoption of these guidelines in Japanese clinical practice, influencing treatment protocols for thousands of patients. His efforts bridge the gap between rigorous evidence synthesis and practical oncology, ensuring that even uncommon thoracic tumors receive standardized, high-quality care. Hanaoka’s dedication to guideline development underscores his role as a pivotal architect of modern thoracic oncology standards, making him an essential resource for clinicians and researchers navigating the nuances of lung and thymic cancer management.

Research Focus

Key Achievements

1
H-Index
1
Papers
2
Total Citations
2
Avg Citations/Paper
🏆 Most Cited Paper
Medical Practice Guidelines for Lung Cancers including malignant pleural mesotheliomas and thymic tumors according to evidence-based medicine. 2024. Edited by the Japan Lung Cancer Society. Chapter 3 Guidelines for thymic epithelial tumors – Summary of recommendations
2 citations · 2025
📈 Most Prolific Year: 2025 (1 Papers)
🤝 Key Collaborators: 17
🏛 Institutions: Osaka University of Pharmaceutical Sciences

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 16 days ago